Answer
Breastfeeding should be discontinued during treatment with gilteritinib fumarate and for at least two months after the last dose because a risk to breastfed children cannot be excluded.
Sources for this answer
- Gilteritinib Astellas 40 mg film-coated tabletsAstellas Pharma Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 7Document updated
Sources checked